Search Results

The AeroEclipse® II Breath Actuated Nebulizer is intended to be used by patients who are under the care or treatment of a licensed health care provider or physician. The device is intended to be used by these patients to administer aerosolized medication prescribed by a physician or health care professional. The intended environments for use include the home, hospitals and clinics.

AeroEclipse® II Breath Actuated Nebulizer

The provided text is a 510(k) clearance letter from the FDA for the AeroEclipse® II Breath Actuated Nebulizer. It indicates that the device has been found substantially equivalent to a legally marketed predicate device. However, this document does not contain specific details about acceptance criteria, performance studies, sample sizes, ground truth establishment, or expert qualifications as typically found in a study report.

The 510(k) clearance process primarily evaluates substantial equivalence based on the device's technological characteristics and intended use compared to a predicate device. It doesn't typically require a separate clinical study with detailed performance metrics and statistical analyses as would be needed for a PMA or de novo submission.

Therefore,Based on the provided text, I cannot complete the table or answer most of the questions as the information is not present within this FDA clearance letter. The letter confirms clearance but does not detail the specific studies, acceptance criteria, or performance data used to demonstrate substantial equivalence internally.

Here's an explanation of what can be inferred or what is missing:

1. A table of acceptance criteria and the reported device performance

• Cannot be provided. The document does not specify any acceptance criteria or reported device performance metrics (e.g., nebulization rate, particle size distribution, drug delivery efficiency) from a performance study. The 510(k) is a regulatory clearance, not a performance report.

2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

• Cannot be provided. The document does not mention any specific test set sample sizes or data provenance.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

• Cannot be provided. This information is not relevant to a 510(k) clearance letter for a nebulizer. Ground truth establishment with experts is typically for diagnostic devices, not for a device like a nebulizer.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

• Cannot be provided. This is not applicable or mentioned in the document.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

• Cannot be provided. MRMC studies are typically for AI-enabled diagnostic devices. This is a nebulizer and does not involve human readers or AI assistance in a diagnostic capacity.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

• Cannot be provided. This device is not an AI algorithm.

7. The type of ground truth used (expert concensus, pathology, outcomes data, etc)

• Cannot be provided. Ground truth, in the context of diagnostic performance, is not applicable to this device and is not mentioned. For a nebulizer, performance is evaluated against engineering specifications and standards (e.g., aerosol output, particle size), not against a "ground truth" derived from patient data in the same way a diagnostic device would.

8. The sample size for the training set

• Cannot be provided. This device does not involve a "training set" in the context of machine learning.

9. How the ground truth for the training set was established

• Cannot be provided. Not applicable to this device.

What the document does tell us:

• Trade/Device Name: AeroEclipse® II Breath Actuated Nebulizer
• Regulation Number: 868.5630
• Regulation Name: Nebulizer
• Regulatory Class: II
• Product Code: CAF
• Intended Use: To be used by patients under the care or treatment of a licensed healthcare provider or physician to administer aerosolized medication prescribed by a physician or healthcare professional. Intended environments include home, hospitals, and clinics.
• Regulatory Mechanism: 510(k) premarket notification, cleared based on substantial equivalence to a legally marketed predicate device.

Ask a specific question about this device